W
hen medicines are introduced, they tend to draw the focus of scientific and clinical attention away from the old and familiar to what is new and exciting. Biological diseasemodifying antirheumatic drugs (DMARDs) are a case in point and the spotlight has recently spared the older nonbiological DMARDs. This has now been rectified with the publication of a new evidence-based guideline from the British Society for Rheumatology and British Health Professionals in Rheumatology (BSR/BHPR) on the use of non-biological DMARDs in rheumatic disease. 1 
Overview
The guideline, an update to the BSR/ BHPR 2008 document, describes measures to ensure safe prescribing of non-biological DMARDs in adults (>16 years old), covering pretreatment screening, the impact of co-morbidities, monitoring for toxicity, treatment during intercurrent illness or surgery, and shared care guidelines. It is intended for all healthcare professionals involved in the care of patients with rheumatic disease in primary and secondary care; it is also for patients (the authors included a patient representative), though they will probably find the executive summary 2 more accessible than the full guideline summarising the evidence base.
The guideline covers 12 agents: apremilast, azathioprine, ciclosporin, hydroxychloroquine, leflunomide, mepacrine, methotrexate, minocycline, mycophenolate mofetil, sodium aurothiomalate (gold), sulfasalazine and tacrolimus. It does not consider their indications or drug interactions, nor does it cover biological DMARDs, new non-biological DMARDs such as the janus kinase (JAK) inhibitors, treatment in the under16s, or prescribing for women who are pregnant or breastfeeding (most of which is covered in separate guidelines).
Pretreatment and initiating DMARDs
Some measures are recommended before prescribing any DMARD (see Table 1 ). Although the guideline provides suppor ting evidence, several need no justification (eg the value of Prescribing and monitoring non-biological DMARDs
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The British Society for Rheumatology and British Health Professionals in Rheumatology (BSR/BHPR) recently updated their guidance on prescribing and monitoring non-biological disease-modifying antirheumatic drugs (DMARDs) for patients with rheumatic disease. This article provides an overview of the main recommendations of the new guideline.
• The decision to initiate a DMARD should be made with the patient/carer and be supervised by an expert in the management of rheumatic diseases • Patients should be provided with education about their treatment to promote self-management • When appropriate, patients should be advised about the impact of DMARD therapy upon fertility, pregnancy and breastfeeding • Baseline assessment should include height, weight, blood pressure and laboratory evaluation (full blood count, calculated glomerular filtration rate, alanine aminotransferase and/or aspartate aminotransferase, albumin) • Patients should be assessed for co-morbidities as these may influence DMARD choice, including evaluation for respiratory disease and screening for occult viral infection • Vaccinations against pneumococcus and influenza are recommended Patients should be screened for hepatitis B and C and for HIV infection. DMARDs can reactivate hepatitis B (little is known about their impact on hepatitis C) and may increase the risk of infection for people living with HIV.
People with rheumatic disease who are taking a DMARD are included in the group of under-65s considered at risk and who should receive vaccination. This is the responsibility of primary care but uptake among people with rheumatic disease is low. Ideally, pneumococcal vaccine should be administered before starting a DMARD; individuals who are severely immunocompromised require a different schedule (as set out in The Green Book 2 ). Live vaccines are normally avoided in immunocompromised individuals and this includes those travelling to areas where yellow fever is prevalent.
A low level of immunosuppression (eg standard-dose DMARDs, prednisolone up to 20mg daily) is not considered an absolute contraindication to vaccination but clinician discretion is advised. People with rheumatic diseases are at increased risk of shingles but there is no recommendation to offer the vaccine below the usual age threshold of 69 years.
There are also specific measures to take before prescribing some DMARDs. All patients to be treated with methotrexate should take folic acid 5mg weekly (taken on a different day from methotrexate); thiopurine methyltransferase status should be assessed before prescribing azathioprine (0.3% of people have low activity and cannot metabolise azathioprine); and a formal ophthalmic examination including objective retinal assessment (not simple visual acuity tests) should be carried out within one year of starting treatment with hydroxychloroquine.
Drug
Accumulates Most DMARDs undergo some renal excretion, and patients with chronic kidney disease often require dose reduction and more frequent monitoring. Table 2 summarises the manufacturers' recommendations for dose adjustment, depending on the stage of chronic kidney disease.
Cardiovascular disease is not a contraindication to DMARD therapy: treatment of rheumatoid arthritis -notably with methotrexate, leflunomide or sulfasalazine -is associated with a reduction in cardiovascular risk. The risk of new cancers during DMARD treatment is no greater than in the population at large. Prior malignancy is generally not a contraindication but evidence is limited and there are exceptions: lymphoproliferative disorder induced by methotrexate is a clear contraindication to further treatment and a patient with skin cancer should be monitored by a dermatologist. The risk should be assessed individually for each patient.
Monitoring
The guideline recommends a standard schedule for monitoring patients newly prescribed a DMARD or when a second DMARD is initiated (see Table 3 ) but again there are many exceptions. No routine monitoring is necessary with apremilast, hydroxychloroquine, mepacrine or minocycline. Standard monitoring is recommended for azathioprine, sodium aurothiomalate, leflunomide and mycophenolate mofetil, and for 12 months for sulfasalazine.
Monthly monitoring should be extended long-term for ciclosporin, methotrexate plus leflunomide and tacrolimus but less frequent monitoring can be considered for patients who have been stable for 12 months. There are also recommendations for additional monitoring for ciclosporin and tacrolimus (blood pressure and glucose at every visit), leflunomide (blood pressure and weight at every visit), sodium aurothiomalate (urinalysis for blood and protein before each dose) and when hydroxychloroquine is taken for more than five years (annual eye assessment, ideally including optical coherence tomography).
Therapeutic drug monitoring is useful with ciclosporin and tacrolimus but, compared with the transplantation setting, the doses used in rheumatology are smaller and blood levels have not been correlated with efficacy; monitoring frequency may therefore be lower.
Perioperative management
Most patients who undergo ar throplasty are being treated with a DMARD and/or a steroid at the time. The decision whether to stop or continue therapy depends on the risks of a disease flare (affecting 10-20% of patients with rheumatoid arthritis) or an infection (more likely with active rheumatoid ar thritis and immunosuppression). These risks vary between DMARDs and may be greater with leflunomide than methotrexate (for which there is most evidence). There is relatively little evidence on which to base a decision for other DMARDs.
The guideline recommends that DMARDs should not be stopped routinely during the perioperative period but the decision should be individualised for patients undergoing a high-risk procedure. Risk factors include longer duration surgery, class 3/4 procedures, older age, impaired renal function and co-morbidity. Steroid exposure should be minimised before surgery and it is not usually necessary to increase the dose to prevent adrenal insufficiency.
Intercurrent infection
The risk of serious infection (eg infection requiring intravenous antibiotics or hospitalisation) is increased in many people with inflammatory arthritis and Check FBC, creatinine/calculated GFR, ALT and/or AST and albumin every:
• Two weeks until on stable dose for six weeks • Then, once on stable dose, monthly FBC, creatinine/calculated GFR, ALT and/or AST and albumin for three months • Thereafter, FBC, creatinine/calculated GFR, ALT and/or AST and albumin at least every 12 weeks • More frequent monitoring is appropriate in patients at higher risk of toxicity • Dose increases should be monitored by FBC, creatinine/calculated GFR, ALT and/or AST and albumin: -every two weeks until on stable dose for six weeks -then revert back to previous schedule FBC = full blood count; GFR = glomerular filtration rate; ALT = alanine aminotransferase; AST = aspartate aminotransferase Table 4 . Criteria for contacting the rheumatology team to consider suspending DMARD treatment under a shared care agreement prescriber.co.uk even more so in those with rheumatoid arthritis. Risk factors include co-morbidity, use of steroids, increased disease activity and longer use of some DMARDs.
Methotrexate, leflunomide, sulfasalazine, azathioprine, apremilast, mycophenolate mofetil, ciclosporin and tacrolimus should be temporarily discontinued during a serious infection (but not in minor infections) until the patient has recovered. Treatment with minocycline, hydroxychloroquine or sodium aurothiomalate can be continued during minor or serious infections.
Shared care
Treatment with a DMARD is usually initiated in secondary care and continued long-term in primary care. When this occurs, a local written shared care agreement should specify the responsibilities of the patient, the primary care team and the rheumatology team. Responsibility for ensuring adherence to monitoring guidance rests with the prescriber. Table 4 lists the criteria for urgently contacting the rheumatology team for action within one day but these should not be interpreted rigidly: trends in these parameters should also be taken into account.
Methotrexate, the most frequently prescribed DMARD, has been associated with clinically significant prescribing and administration risks and the National Patient Safety Agency has published guidance to support safer prescribing (see Table 5 ). 4 This guidance also warns of the potential for confusion between the two strengths of methotrexate tablet (2.5mg and 10mg) and different devices for parenteral use.
Summary
When expensive biological DMARDs steal the limelight, the mundane nonbiologicals can be underestimated but they remain effective though potentially toxic drugs. This guideline provides a clear description of the practicalities involved in prescribing DMARDs in adults, including both general and drug-specific points for best clinical practice. It is relevant to everyone involved in using these agents, establishing the principle that care and vigilance are needed to ensure both appropriate and safe use.
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When initiating treatment, information is available to provide to the patient on the risks and benefits of methotrexate, confirmation of understanding/consent, baseline tests conducted, the need for monitoring and the monitoring schedule. A patient-held recording document is issued and its use explained.
Shared care guidelines should clearly state:
• Prescribing and monitoring responsibilities • How often will blood tests be conducted and in which location • Which clinician will be responsible for receipt and review of the results • Who will communicate necessary dosage changes to the patient (and to the GP if hospital reviewed for the GP prescriber) • Who will record test results in the patient-held record document • Trusts without shared care guidelines must make similar appropriate arrangements
When prescribing:
• All prescribers should avoid the use of 'as directed' in prescribing -a specific dose must be applied to each prescription • Patients often understand their dose by number of tablets rather than milligrams; quantity and frequency of dose should be regularly discussed with the patient • Repeat prescriptions should be removed from the surgery repeats pile and retained separately for prescriber review prior to authorising by signature (shading the prescription signature space on FP10 or WP10 forms to alert the prescriber to high-risk drugs might help) • Beware patients attending with other symptoms -signs of toxicity or intolerance may present as, for example, breathlessness, dry persistent cough, vomiting and diarrhoea • Patients receiving methotrexate may be admitted to any ward or receive outpatient treatment for co-existing conditions, and staff in all areas may therefore be involved in continuity of prescribing, monitoring or administration • Full medicines reconciliation, conducted by pharmacists, should be undertaken on admission, and prescribing, monitoring and administration requirements recorded in the patient's notes • It is the prescriber's responsibility to record the correct dosage and frequency on the hospital drug administration chart and to strike out the six days of the week when a dose must not be administered in the administration section on the chart • Handwritten prescriptions and discharge summary information must be complete and legible and include in full the form, strength, dose and directions 
